The gut microbiome in intravenous immunoglobulin‐treated chronic inflammatory demyelinating polyneuropathy

• Published in: European journal of neurology Vol. 30; no. 11; pp. 3551 - 3556
• Main Authors: Svačina, Martin K. R., Sprenger‐Svačina, Alina, Tsakmaklis, Anastasia, Rüb, Alina M., Klein, Ines, Wüstenberg, Hauke, Fink, Gereon R., Lehmann, Helmar C., Vehreschild, Maria J. G. T., Farowski, Fedja
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.11.2023
• Subjects: Autoimmune diseases; Autoimmunity; Composition; Demyelination; Digestive system; Fatty acids; Females; Firmicutes; Gene sequencing; Gut microbiota; Immunoglobulins; Inflammation; Intestinal microflora; Intravenous administration; Microbiomes; Microbiota; Microorganisms; Peripheral nerves; Pilot projects; Polyneuropathy; rRNA 16S; immune neuropathies; autoimmunity; intestinal barrier; firmicutes; short-chain fatty acids (SCFA)
• ISSN: 1351-5101; 1468-1331; 1468-1331
• DOI: 10.1111/ene.15679

The gut microbiome is involved in autoimmunity. Data on its composition in chronic inflammatory demyelinating polyneuropathy (CIDP), the most common chronic autoimmune disorder of peripheral nerves, are currently lacking. In this monocentric exploratory pilot study, stool samples were prospectively collected from 16 CIDP patients (mean age 58 ± 10 years, 25% female) before and 1 week after administration of intravenous immunoglobulin (IVIg). Gut microbiota were analyzed via bacterial 16S rRNA gene sequencing and compared to 15 age-matched healthy subjects (mean age 59 ± 15 years, 66% female). The gut microbiota of CIDP patients showed an increased alpha-diversity (p = 0.005) and enrichment of Firmicutes, such as Blautia (p = 0.0004), Eubacterium hallii (p = 0.0004), or Ruminococcus torques (p = 0.03), and of Actinobacteriota (p = 0.03) compared to healthy subjects. IVIg administration did not alter the gut microbiome composition in CIDP in this short-term observation (p = 0.95). The gut microbiome in IVIg-treated CIDP shows distinct features, with increased bacterial diversity and enrichment of short-chain fatty acid producing Firmicutes. IVIg had no short-term impact on the gut microbiome in CIDP patients. As the main limitation of this exploratory pilot study was small cohort size, future studies also including therapy-naïve patients are warranted to verify our findings and to explore the impact of long-term IVIg treatment on the gut microbiome in CIDP.